What is new in the treatment of pulmonary arterial hypertension?;¿Qué es lo nuevo en el tratamiento de la hipertensión arterial pulmonar?

Archivos de Cardiologia de Mexico

Volumn 73, Issue SUPPL. 1, 2003, Pages

  Pulido Zamudio, Tomás ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Bosentan; Epoprostenol; Pulmonary arterial hypertension

Indexed keywords

ARGININE; BERAPROST; BOSENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; UNIPROST; DRUG DERIVATIVE; ENDOTHELIN RECEPTOR; SULFONAMIDE;

CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG APPROVAL; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SURVIVAL; DRUG ANTAGONISM; FORECASTING;

EPOPROSTENOL; FORECASTING; HUMANS; HYPERTENSION, PULMONARY; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 0042469293     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. MONCADA S, GRYLEWSKI R, BUNTING S, VANE JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665.
2. BARST RJ, RUBIN LJ, LONG WA, MCGOON MD, RICH S, BADESCH D, ET AL: A comparison of continuous intravenous Epoprostenol (Prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
3. SIMONNEAU G, BARST RJ, GALIÉ, N, NAEIJE R, RICH S, BOURGE RC, ET AL: Continuous subcutaneous infusion of Treprostinil, a Prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804.
4. GALIÉ N, HUMBERT M, VACHIÉRY JL, VIZZA CD, KNEUSSL M, MANES A, ET AL: Effects of beraprost, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502.
5. OLSCHEWSKI H, SIMONNEAU G, GALIÉ N, HIGENBOTTAM T, NAEIJE R, RUBIN LJ, ET AL: inhaled Iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
6. MCLAUGHLIN V, SHILLINGTON A, RICH S: Survival in primary pulmonary hypertension: The impact of Epoprostenol therapy. Circulation 2002; 106: 1477-1482.
7. TUDER RM, COOL CD, YEAGER M, TARASEVICIENE-STEWART L, BULL TM, VOELKEL N: The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001; 22: 405-418.
8. RUBIN LJ, BADESCH D, BARST RJ, GALIÉ N, BLACK CM, KEOGH A, ET AL: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
9. BARST RJ, RICH S, WIDLITZ A, HORN E, MCLAUGHLIN V, MCFARLIN J: Clinical efficacy of sitaxsentan, an Endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: Open-label pilot study. Chest 2002; 121: 1860-1868.
10. NAGAYA N, UEMATSU M, OYA H, SATO N, SAKAMAKI F, KYOTANI S, ET AL: Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 2002; 163: 887-891.
11. MICHELAKIS E, TYMCHAK W, LIEN D, WEBSTER L, HASHIMOTO K, ARCHER S: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with nitric oxide. Circulation 2002; 105: 2398-2403.